Salary: Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at £34,344 until the successful completion of their viva.
This role is eligible for ICR Sponsorship. Support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here.
Duration of Contract: 12 months
Hours per week: 35 hours per week
Closing Date: 16th April 2023
The Division of Clinical Studies has a vacancy for a post-doctoral research fellow, to work in our Cancer Biomarker team under the leadership of Professor Johann de Bono. The programme aims to use circulating tumour cells & plasma nucleic acids to develop biomarkers for patient selection, evaluating response to novel agents and identifying mechanisms of resistance in castration-resistant prostate cancer.
For general information on Post Doc's at The ICR can be found here.
Key Requirements
The successful candidate must have experience in molecular & cellular biology techniques and experience in developing sequencing assays. Familiarity with contemporary approaches to target validation and drug discovery are desirable.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years
Department/Directorate Information:
Within the Institute of Cancer Research, the Divisions of Clinical Studies and Cancer Therapeutics play a key role in developing new drugs for treating cancer. It comprises both clinical and laboratory staff, covering a range of interests and tumour types. All the clinical and laboratory facilities are based in the Sutton branch of The Institute and Royal Marsden Hospital, and there is a special responsibility for the Drug Development Unit.
Professor Johann de Bono’s team conducts biomarker-driven clinical and translational research to accelerate the development of novel cancer therapies and improve understanding of cancer biology, drug sensitivity and resistance. His team focuses on improving prostate cancer care that have led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide and olaparib as well more recently ipatasertib and lutetium-PSMA. His team consists of basic and clinical scientists, which is embedded in a vibrant world-class research environment.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Professor Johann de Bono on
[email protected] Why work for us?
As a member of staff, you'll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
